KX 01

Drug Profile

KX 01

Alternative Names: KX-2391; KX01

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kinex Pharmaceuticals
  • Developer Athenex; Hanmi Pharmaceutical; Kinex Pharmaceuticals; PharmaEssentia Corporation
  • Class Acetamides; Amides; Antineoplastics; Antipsoriatics; Morpholines; Phenyl ethers; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Interleukin 2 inhibitors; Keratinocyte inhibitors; Src-Family kinase inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Actinic keratosis
  • Phase II Psoriasis
  • Phase I/II Solid tumours
  • No development reported Acute myeloid leukaemia; Prostate cancer

Most Recent Events

  • 12 Sep 2018 Athenex will re-acquire the rights to KX 01 oral formulation from Hanmi Pharmaceutical for Korea, China and other Asian territories
  • 14 Aug 2018 Athenex and Almirall plan regulatory submissions for Actinic keratosis
  • 26 Jul 2018 Efficacy data from two phase III trial in Actinic keratosis released by Athenex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top